Meihong Li, Ph.D.

Genomics Scientist II

Apply and develop Oxford Nanopore technologies and chromosome conformation capture techniques in various biological settings such as cancer.

My Ph.D work in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, focused on establishing high throughput screening models for anticancer drugs, and investigating pharmacology of candidate compounds. As a postdoctoral researcher at UConn Health, I was driven to explore the mechanisms and functions of a bioactive lipid, sphingosine-1-phosphate (S1P), and its receptors on tumor growth and progression in pediatric cancers, and further developing new anticancer drugs targeting the sphingolipid pathway. The magical application of RNA-seq in my previous work fascinated me into the realm of genomic medicine.